{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:17:10Z","timestamp":1762899430176,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BE 4572\/4-1","INST 268\/281-1 FUGG"],"award-info":[{"award-number":["BE 4572\/4-1","INST 268\/281-1 FUGG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.bmcl.2017.06.012","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T19:30:29Z","timestamp":1496518229000},"page":"3349-3352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A small-molecule screen identifies the antitrypanosomal agent suramin and analogues NF023 and NF449 as inhibitors of STAT5a\/b"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6977-1407","authenticated-orcid":false,"given":"Angela","family":"Berg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-7696","authenticated-orcid":false,"given":"Thorsten","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2017.06.012_b0005","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2017.06.012_b0010","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1039\/c3cs35449k","article-title":"Progress towards the development of SH2 domain inhibitors","volume":"42","author":"Kraskouskaya","year":"2013","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmcl.2017.06.012_b0015","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/cbic.200800274","article-title":"Signal transducers and activators of transcription as targets for small organic molecules","volume":"9","author":"Berg","year":"2008","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bmcl.2017.06.012_b0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1101\/gad.1643908","article-title":"Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B","volume":"22","author":"Hennighausen","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.bmcl.2017.06.012_b0025","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/cbic.200700701","article-title":"Discovery of chromone-based inhibitors of the transcription factor STAT5","volume":"9","author":"M\u00fcller","year":"2008","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bmcl.2017.06.012_b0030","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/anie.200906555","article-title":"A scaffold-tree-merging strategy for prospective bioactivity annotation of gamma-pyrones","volume":"49","author":"Wetzel","year":"2010","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmcl.2017.06.012_b0035","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/jm200720n","article-title":"Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity","volume":"55","author":"Page","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.06.012_b0040","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1021\/ml500165r","article-title":"Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein","volume":"5","author":"Cumaraswamy","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2017.06.012_b0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1515\/hmbci-2012-0009","article-title":"Progress towards direct inhibitors of Stat5 protein","volume":"10","author":"Cumaraswamy","year":"2012","journal-title":"Horm Mol Biol Clin Investig"},{"key":"10.1016\/j.bmcl.2017.06.012_b0050","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1535-7163.MCT-14-0883","article-title":"Structure-based screen identifies a potent small molecule inhibitor of stat5a\/b with therapeutic potential for prostate cancer and chronic myeloid leukemia","volume":"14","author":"Liao","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2017.06.012_b0055","doi-asserted-by":"crossref","first-page":"36044","DOI":"10.1038\/srep36044","article-title":"Antagonizing STAT5B dimerization with an osmium complex","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmcl.2017.06.012_b0060","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1021\/cb2001796","article-title":"Selective Targeting of Disease-Relevant Protein Binding Domains by O-Phosphorylated Natural Product Derivatives","volume":"6","author":"Gr\u00e4ber","year":"2011","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2017.06.012_b0065","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1002\/anie.201410672","article-title":"Nanomolar inhibitors of the transcription factor STAT5b with high selectivity over STAT5a","volume":"54","author":"Elumalai","year":"2015","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmcl.2017.06.012_b0070","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1021\/acschembio.5b00817","article-title":"Phosphorylation of capsaicinoid derivatives provides highly potent and selective inhibitors of the transcription factor STAT5b","volume":"10","author":"Elumalai","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2017.06.012_b0075","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41598-017-00920-3","article-title":"Rational development of Stafib-2: a selective, nanomolar inhibitor of the transcription factor STAT5b","volume":"7","author":"Elumalai","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmcl.2017.06.012_b0080","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1016\/j.bmc.2017.05.039","article-title":"Halogen-substituted catechol bisphosphates are potent and selective inhibitors of the transcription factor STAT5b","volume":"25","author":"Elumalai","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2017.06.012_b0085","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ab.2008.01.017","article-title":"A high-throughput assay for signal transducer and activator of transcription 5b based on fluorescence polarization","volume":"375","author":"M\u00fcller","year":"2008","journal-title":"Anal Biochem"},{"key":"10.1016\/j.bmcl.2017.06.012_b0090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.bmcl.2017.06.012_b0095","first-page":"2239","article-title":"Suramin: a novel antineoplastic agent with multiple potential mechanisms of action","volume":"53","author":"Stein","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2017.06.012_b0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0028-3908(98)00158-0","article-title":"Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors","volume":"38","author":"Soto","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmcl.2017.06.012_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(03)01761-8","article-title":"NF449, a novel picomolar potency antagonist at human P2X1 receptors","volume":"470","author":"Hulsmann","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmcl.2017.06.012_b0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ejmech.2004.01.007","article-title":"Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist","volume":"39","author":"Kassack","year":"2004","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2017.06.012_b0115","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1073\/pnas.95.1.346","article-title":"Gsalpha-selective G protein antagonists","volume":"95","author":"Hohenegger","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2017.06.012_b0120","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1128\/MCB.16.4.1622","article-title":"Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response","volume":"16","author":"Quelle","year":"1996","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2017.06.012_b0125","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12935-015-0196-y","article-title":"Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression","volume":"15","author":"Li","year":"2015","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.bmcl.2017.06.012_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8070066","article-title":"A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers","volume":"8","author":"Ahmed","year":"2016","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmcl.2017.06.012_b0135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jnci\/84.7.489","article-title":"Effects of suramin on in vitro growth of fresh human tumors","volume":"84","author":"Taylor","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bmcl.2017.06.012_b0140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0031-6997(25)00445-4","article-title":"Recent research on the biological activity of suramin","volume":"45","author":"Voogd","year":"1993","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmcl.2017.06.012_b0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF00685609","article-title":"Suramin: an anticancer drug with unique biological effects","volume":"32","author":"Larsen","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bmcl.2017.06.012_b0150","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1042\/BJ20150913","article-title":"Inhibition of Wnt signalling and breast tumour growth by the multi-purpose drug suramin through suppression of heterotrimeric G proteins and Wnt endocytosis","volume":"473","author":"Koval","year":"2016","journal-title":"Biochem J"},{"key":"10.1016\/j.bmcl.2017.06.012_b0155","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/prot.24766","article-title":"NF023 binding to XIAP-BIR1: searching drugs for regulation of the NF-kappaB pathway","volume":"83","author":"Cossu","year":"2015","journal-title":"Proteins"},{"key":"10.1016\/j.bmcl.2017.06.012_b0160","doi-asserted-by":"crossref","first-page":"20644","DOI":"10.1074\/jbc.M109.083626","article-title":"NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells","volume":"285","author":"Krejci","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2017.06.012_b0165","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cmdc.201300563","article-title":"Delivery of suramin as an antiviral agent through liposomal systems","volume":"9","author":"Mastrangelo","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2017.06.012_b0170","doi-asserted-by":"crossref","first-page":"12608","DOI":"10.1016\/S0021-9258(18)37798-6","article-title":"Rapid turnover of the platelet-derived growth factor receptor in sis-transformed cells and reversal by suramin. Implications for the mechanism of autocrine transformation","volume":"263","author":"Huang","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2017.06.012_b0175","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1039\/c0cc04796a","article-title":"Design and application of esterase-labile sulfonate protecting groups","volume":"47","author":"Rusha","year":"2011","journal-title":"Chem Commun"},{"key":"10.1016\/j.bmcl.2017.06.012_b0180","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1039\/C7OB00063D","article-title":"Reductively-labile sulfonate ester protecting groups that are rapidly cleaved by physiological glutathione","volume":"15","author":"Choi","year":"2017","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmcl.2017.06.012_b0185","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/cmdc.201500015","article-title":"Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo","volume":"10","author":"Grosskopf","year":"2015","journal-title":"ChemMedChem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X17306157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X17306157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:18:46Z","timestamp":1760771926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X17306157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":37,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0960894X17306157"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2017.06.012","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A small-molecule screen identifies the antitrypanosomal agent suramin and analogues NF023 and NF449 as inhibitors of STAT5a\/b","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2017.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}